» Articles » PMID: 32335986

Clinicopathological Characteristics of Combined Hepatocellular Cholangiocarcinoma from the Viewpoint of Patient Prognosis After Hepatic Resection: High Rate of Early Recurrence and Its Predictors

Abstract

Aim: Combined hepatocellular cholangiocarcinoma (cHCC-CCA) is a very rare subtype of primary liver carcinoma; therefore, its clinicopathological characteristics have not yet been elucidated in detail. The aim of the study was to reveal the clinicopathological characteristics and prognostic factors of cHCC-CCA after hepatic resection (HR) METHODS: A total of 124 patients who underwent curative HR for cHCC-CCA between 2000 and 2016 were enrolled in this multi-institutional study conducted by the Kyushu Study Group of Liver Surgery. Clinicopathological analysis was performed from the viewpoint of patient prognosis.

Results: A total of 62 patients (50%) had early recurrence within 1.5 years after HR, including 36 patients (58%) with extrahepatic recurrence. In contrast, just four patients (3%) had late recurrence occurring >3 years after HR. The independent predictors of early recurrence were as follows: des-gamma carboxyprothrombin >40 mAU/mL (odds ratio 26.2, P = 0.0117), carbohydrate antigen 19-9>37 IU/l (odds ratio 18.0, P = 0.0200), and poorly differentiated HCC or CCA (odds ratio 11.2, P = 0.0259).

Conclusions: Half of the patients with cHCC-CCA had early recurrence after HR. Preoperative elevation of des-gamma carboxyprothrombin or carbohydrate antigen 19-9 and the existence of poorly differentiated components of HCC or CCA in resected specimens are predictors of its early recurrence.

Citing Articles

Evaluation of combined hepatocellular-cholangiocarcinoma using CEUS LI-RADS: correlation with pathological characteristics.

Bao J, Nie Z, Wang Q, Chen Y, Wang K, Liu X Abdom Radiol (NY). 2024; 50(2):646-655.

PMID: 39150545 DOI: 10.1007/s00261-024-04519-x.


Treatments and prognostic outcomes of combined hepatocellular-cholangiocarcinoma with distant metastasis: an analysis based on SEER data.

Zhang L, Lu Y, Chen Y, Lu X, Lao X Transl Cancer Res. 2024; 13(7):3318-3327.

PMID: 39145067 PMC: 11319941. DOI: 10.21037/tcr-24-447.


Letter to the editor Re "Nomogram based on clinical and preoperative CT features for predicting the early recurrence of combined hepatocellular-cholangiocarcinoma: a multicenter study".

Xie Y, Wang J, Zou Y Radiol Med. 2024; 129(4):665-666.

PMID: 38512607 DOI: 10.1007/s11547-024-01794-y.


Preoperative evaluation of MRI features and inflammatory biomarkers in predicting microvascular invasion of combined hepatocellular cholangiocarcinoma.

Zhang J, Dong W, Liu W, Fu J, Liao T, Li Y Abdom Radiol (NY). 2023; 49(3):710-721.

PMID: 38112787 PMC: 10909765. DOI: 10.1007/s00261-023-04130-6.


Implications of ultrasound-based deep learning model for preoperatively differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and intrahepatic cholangiocarcinoma.

Chen J, Zhang W, Bao J, Wang K, Zhao Q, Zhu Y Abdom Radiol (NY). 2023; 49(1):93-102.

PMID: 37999743 DOI: 10.1007/s00261-023-04089-4.